Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
1,582,162
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
68,914
-
Shares change
-
+8,066
-
Total reported value, excl. options
-
$131,127
-
Value change
-
+$15,393
-
Number of buys
-
3
-
Number of sells
-
-3
-
Price
-
$1.90
Significant Holders of Evoke Pharma, Inc. - Common Shares (EVOK) as of Q1 2023
13 filings reported holding EVOK - Evoke Pharma, Inc. - Common Shares as of Q1 2023.
Evoke Pharma, Inc. - Common Shares (EVOK) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68,914 shares
of 1,582,162 outstanding shares and own 4.4% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (29,851 shares), GEODE CAPITAL MANAGEMENT, LLC (20,894 shares), RENAISSANCE TECHNOLOGIES LLC (11,178 shares), Tower Research Capital LLC (TRC) (3,985 shares), BlackRock Inc. (1,473 shares), UBS Group AG (1,107 shares), NewEdge Advisors, LLC (208 shares), Concord Wealth Partners (114 shares), Lindbrook Capital, LLC (83 shares), and WELLS FARGO & COMPANY/MN (16 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.